Yellow Fever Vaccination: Why This Is Not a Standard Travel Vaccine

Yellow fever stands apart from most travel vaccines in several important respects. It is the only vaccine for which proof of vaccination may be legally required as a condition of entry into certain countries. It is administered only at designated yellow fever vaccination centres. It is a live vaccine with contraindications affecting a meaningful proportion of travellers. And the disease it protects against carries a mortality rate of 20 to 50 percent in its severe form.

For these reasons, yellow fever requires particular attention in travel health planning. This guide explains what yellow fever is, who needs the vaccine, who should not have it and what the entry certification requirements mean in practice.

What Is Yellow Fever?

Yellow fever is a viral haemorrhagic fever caused by the yellow fever virus, an Aedes mosquito-borne flavivirus endemic in sub-Saharan Africa and tropical South America. The name derives from one of its hallmark features in severe cases: jaundice, a yellowing of the skin and eyes caused by severe liver damage.

The majority of people infected with yellow fever experience either no symptoms or a mild febrile illness with fever, headache and muscle pain that resolves within a week. However, approximately 15 percent of patients progress to a severe toxic phase, characterised by return of high fever, liver failure with jaundice, renal failure, haemorrhagic complications and cardiovascular instability. Within this severe group, case fatality rates of 20 to 50 percent are reported.

There is no specific antiviral treatment for yellow fever. Once in the severe toxic phase, management is supportive and the prognosis is poor. Vaccination is the only reliable clinical protection.

Geographic Distribution and Entry Requirements

Yellow fever is endemic across much of sub-Saharan Africa and tropical South America. The risk is not uniformly distributed even within endemic countries: some regions within countries carry higher risk due to mosquito density, land use and ecological factors. Country-specific risk maps are published by the National Travel Health Network and Centre (NaTHNaC) and updated regularly.

International Health Regulations (IHR) allow countries to require proof of yellow fever vaccination from travellers arriving from countries where yellow fever transmission occurs. Proof must be provided in the form of an International Certificate of Vaccination or Prophylaxis (ICVP), the yellow vaccination booklet, showing vaccination at a designated yellow fever centre. Under current WHO regulations, yellow fever vaccination is considered to confer lifelong protection and the ICVP no longer carries a ten-year expiry date, a change introduced in 2016.

Failure to carry a valid ICVP when required can result in refusal of entry, quarantine or being required to receive the vaccine at the point of entry under controlled conditions. Requirements vary by country and can also depend on connecting flight itineraries, not just the final destination.

Who Should Receive the Yellow Fever Vaccine?

Yellow fever vaccination is recommended for travellers visiting endemic areas with genuine risk of yellow fever transmission, and for those required to show proof of vaccination for entry purposes. These are not always the same group, as some countries require proof from all arriving travellers regardless of their individual exposure risk.

The decision to vaccinate requires clinical assessment, and this is not a formality. Yellow fever vaccine is a live attenuated vaccine. It produces genuine (attenuated) viral infection, which is why it provides such long-lasting immunity, but also why it carries a rare but real risk of serious adverse events in certain patient groups.

Yellow Fever Vaccine Associated Adverse Events

For the vast majority of healthy travellers under 60, yellow fever vaccination is safe and well tolerated. Mild side effects including injection site soreness, headache and low-grade fever occur in a minority of recipients.

Two rare but serious adverse events are recognised. Yellow fever vaccine-associated neurotropic disease (YEL-AND) involves invasion of the nervous system by the attenuated virus and can cause encephalitis. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) resembles severe natural yellow fever with multi-organ involvement. Both are rare, with estimated rates below 1 in 250,000, but are more common in adults over 60 and in those receiving their first dose. This age-related risk profile is one reason why clinical review before vaccination is important, particularly in older travellers.

Designated Yellow Fever Vaccination Centres

Yellow fever vaccination can only be administered and officially certified at centres designated by the National Travel Health Network and Centre (NaTHNaC). Halton Pharmacy in Leeds is a designated yellow fever vaccination centre. Our travel health pharmacists conduct the required clinical assessment before vaccination to ensure the vaccine is appropriate for each patient, and issue the International Certificate of Vaccination or Prophylaxis on the same appointment.

This article is for general information purposes and does not constitute individual clinical advice. Please book a travel health consultation before travelling to yellow fever endemic regions.